Cellectar Biosciences, Inc.

CLRB

$1.80

Name : Cellectar Biosciences, Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $17,013,794.00

EPSttm : -2.21

Cellectar Biosciences, Inc.

$1.80

13.25%

$0.275

CLRB — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

2.06

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

0.04

EPS Last/This Y

5.92

EPS This/Next Y

0.52

Price

1.81

Target Price

11.5

Analyst Recom

Performance Q

-28.57

Upside

-8,947.2%

Beta

0.56

Ticker: CLRB

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-08-28	CLRB	2.55	N/A	N/A	0
2026-08-31	CLRB	2.51	N/A	N/A	0
2026-09-01	CLRB	2.46	N/A	N/A	N/A
2026-09-02	CLRB	2.43	N/A	N/A	0
2026-09-03	CLRB	2.34	N/A	N/A	0
2026-09-04	CLRB	2.39	N/A	N/A	0
2026-09-08	CLRB	2.39	N/A	N/A	0
2026-09-09	CLRB	2.35	N/A	N/A	0
2026-09-10	CLRB	2.35	N/A	N/A	0
2026-09-11	CLRB	2.31	N/A	N/A	0
2026-09-14	CLRB	2.31	N/A	N/A	0
2026-09-15	CLRB	2.33	N/A	N/A	0
2026-09-16	CLRB	2.36	N/A	N/A	0
2026-09-17	CLRB	2.41	N/A	N/A	0
2026-09-18	CLRB	2.39	N/A	N/A	0
2026-09-21	CLRB	2.38	N/A	N/A	0
2026-09-22	CLRB	2.26	N/A	N/A	0
2026-09-23	CLRB	2.05	N/A	N/A	0
2026-09-24	CLRB	2.05	N/A	N/A	0
2026-09-25	CLRB	1.8	N/A	N/A	0
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-08-28	CLRB	2.52	60.5	-	-2.43
2026-08-31	CLRB	2.51	60.5	-	-2.43
2026-09-01	CLRB	2.48	60.5	-	-2.43
2026-09-02	CLRB	2.42	60.5	-	-2.43
2026-09-03	CLRB	2.36	60.5	-	-2.43
2026-09-04	CLRB	2.36	60.5	-	-2.43
2026-09-08	CLRB	2.40	60.5	-	-2.43
2026-09-09	CLRB	2.37	60.5	-	-2.43
2026-09-10	CLRB	2.38	60.5	-	-2.43
2026-09-11	CLRB	2.34	60.5	-	-2.43
2026-09-14	CLRB	2.31	60.5	-	-2.43
2026-09-15	CLRB	2.34	60.5	-	-2.43
2026-09-16	CLRB	2.34	60.5	-	-2.43
2026-09-17	CLRB	2.40	60.5	-	-2.43
2026-09-18	CLRB	2.38	60.5	-	-2.43
2026-09-21	CLRB	2.36	60.5	-	-2.43
2026-09-22	CLRB	2.24	60.5	-	-2.43
2026-09-23	CLRB	2.07	60.5	-	-2.43
2026-09-24	CLRB	2.07	60.5	-	-2.43
2026-09-25	CLRB	1.81	60.5	-	-2.43
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-08-28	CLRB	9.74	63.57	1.74
2026-08-31	CLRB	9.74	61.98	1.74
2026-09-01	CLRB	11.73	61.98	1.74
2026-09-02	CLRB	11.73	61.98	1.74
2026-09-03	CLRB	11.73	61.98	1.74
2026-09-04	CLRB	11.72	61.98	1.74
2026-09-08	CLRB	11.73	61.98	1.74
2026-09-09	CLRB	11.73	61.98	1.74
2026-09-10	CLRB	11.73	61.98	1.74
2026-09-11	CLRB	11.73	61.98	1.80
2026-09-14	CLRB	11.73	61.98	1.80
2026-09-15	CLRB	11.73	61.98	1.80
2026-09-16	CLRB	11.73	61.98	1.80
2026-09-17	CLRB	11.72	61.98	1.80
2026-09-18	CLRB	11.73	61.98	1.80
2026-09-21	CLRB	11.72	61.91	1.80
2026-09-23	CLRB	11.73	61.91	1.80
2026-09-24	CLRB	11.72	61.91	1.80
2026-09-25	CLRB	11.73	61.91	2.06
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-0.57

Avg. EPS Est. Current Quarter

-0.56

Avg. EPS Est. Next Quarter

-0.53

Insider Transactions

11.73

Institutional Transactions

61.91

Beta

0.56

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

99.4

Max Drawdown 5-Year %

-99.3

Target Price

11.5

P/E

Forward P/E

PEG

P/S

P/B

0.5

P/Free Cash Flow

EPS

-4.55

Average EPS Est. Cur. Y

-2.43

EPS Next Y. (Est.)

-1.91

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

1.9

Return on Equity vs Sector %

-100

Return on Equity vs Industry %

-81.4

EPS 1 7Days Diff

-0.3

EPS 1 30Days Diff

-0.26

EBIT Estimation

◆ CLRB Healthcare

$1.80

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

20/20

Pullback

5/25

Volume

3/15

Valuation

12/20

TP/AR

2/10

Options

0/10

RSI

16.8

Range 1M

0.6%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

14/25

Growth

20/30

Estimates

0/20

Inst/Vol

8/15

Options

0/10

EPS Yr

70.9%

EPS NY

21.2%

52W%

0.1%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +538.9% upside

Quality

2/30

Valuation

16/30

Growth

15/25

Stability

7/10

LT Trend

4/5

Upside

+538.9%

Quality

CLRB — P/E HistoricalBiotechnology

Cellectar Biosciences, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 11

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR 121125, an iodine-125 Auger-emitting radioconjugate program; and CLR 225, an actinium-225 based radioconjugate program. The company has collaborative with Orano Med to develop alpha emitter lead-212 conjugated to phospholipid ether series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.

CLRB

Latest News

—

Caricamento notizie per CLRB…

stock quote shares CLRB – Cellectar Biosciences Inc. Stock Price stock today

news today CLRB – Cellectar Biosciences Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch CLRB – Cellectar Biosciences Inc. yahoo finance google finance

stock history CLRB – Cellectar Biosciences Inc. invest stock market

stock prices CLRB premarket after hours

ticker CLRB fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: CLRB

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y